Lurbinectedin
Lurbinectedin
Lurbinectedin (pronounced: lur-bin-ek-ted-in) is a type of antineoplastic agent used in the treatment of certain types of cancer. It is a synthetic compound derived from the marine organism, Ecteinascidia turbinata.
Etymology
The name "Lurbinectedin" is derived from the scientific name of the marine organism from which it is synthesized, Ecteinascidia turbinata. The "lur" is from "tur" in turbinata, "bine" is from "bine" in Ecteinascidia, and "ectin" is from "ectin" in Ecteinascidia.
Usage
Lurbinectedin is used in the treatment of metastatic small cell lung cancer (SCLC) when at least one prior line of systemic therapy has failed. It works by inhibiting the growth of cancer cells, thereby slowing or stopping the spread of cancer in the body.
Related Terms
- Antineoplastic agent: A substance that inhibits the growth and spread of cancerous or potentially cancerous cells.
- Small cell lung cancer (SCLC): A type of lung cancer characterized by small cells that multiply quickly and form large tumors.
- Metastasis: The spread of cancer cells from the place where they first formed to another part of the body.
Side Effects
Common side effects of Lurbinectedin include fatigue, nausea, decreased appetite, vomiting, constipation, respiratory infections, and decreased white blood cell count.
Precautions
Before starting Lurbinectedin treatment, patients should inform their healthcare provider about any other medications they are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.).
External links
- Medical encyclopedia article on Lurbinectedin
- Wikipedia's article - Lurbinectedin
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski